- Home
- WGRX vs ESLA Comparison
WGRX vs ESLA Comparison
Compare WGRX & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- ESLA
- Stock Information
- Founded
- WGRX 2022
- ESLA 2021
- Country
- WGRX United States
- ESLA United States
- Employees
- WGRX N/A
- ESLA N/A
- Industry
- WGRX Other Pharmaceuticals
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WGRX Health Care
- ESLA Health Care
- Exchange
- WGRX Nasdaq
- ESLA Nasdaq
- Market Cap
- WGRX 43.9M
- ESLA 48.9M
- IPO Year
- WGRX 2025
- ESLA N/A
- Fundamental
- Price
- WGRX $0.66
- ESLA $2.47
- Analyst Decision
- WGRX
- ESLA Strong Buy
- Analyst Count
- WGRX 0
- ESLA 1
- Target Price
- WGRX N/A
- ESLA $16.00
- AVG Volume (30 Days)
- WGRX 41.9M
- ESLA 461.1K
- Earning Date
- WGRX 11-19-2025
- ESLA 11-20-2025
- Dividend Yield
- WGRX N/A
- ESLA N/A
- EPS Growth
- WGRX N/A
- ESLA N/A
- EPS
- WGRX N/A
- ESLA N/A
- Revenue
- WGRX $36,738,599.00
- ESLA N/A
- Revenue This Year
- WGRX N/A
- ESLA N/A
- Revenue Next Year
- WGRX N/A
- ESLA N/A
- P/E Ratio
- WGRX N/A
- ESLA N/A
- Revenue Growth
- WGRX 82384.51
- ESLA N/A
- 52 Week Low
- WGRX $0.34
- ESLA $0.70
- 52 Week High
- WGRX $7.04
- ESLA $3.15
- Technical
- Relative Strength Index (RSI)
- WGRX 47.00
- ESLA 59.55
- Support Level
- WGRX $0.61
- ESLA $2.20
- Resistance Level
- WGRX $0.82
- ESLA $3.15
- Average True Range (ATR)
- WGRX 0.13
- ESLA 0.42
- MACD
- WGRX 0.03
- ESLA 0.01
- Stochastic Oscillator
- WGRX 27.76
- ESLA 58.28
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.